Financials Scandinavian ChemoTech AB

Equities

CMOTEC B

SE0009242654

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Stockholm 09:41:27 2024-05-03 am EDT 5-day change 1st Jan Change
2.15 SEK -1.83% Intraday chart for Scandinavian ChemoTech AB -4.02% -20.37%

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Capitalization 1 81.91 164.1 60.67 38.57 38.57 -
Enterprise Value (EV) 1 81.91 164.1 60.67 43.97 32.37 38.57
P/E ratio -5.72 x - -2.21 x -1.73 x - -
Yield - - - - - -
Capitalization / Revenue 57.4 x 3,349 x - 15.6 x 7.71 x 3.98 x
EV / Revenue 57.4 x 3,349 x - 15.6 x 6.47 x 3.98 x
EV / EBITDA - -11.5 x - -2.5 x -1.89 x -2.49 x
EV / FCF - - - -2.36 x - -
FCF Yield - - - -42.3% - -
Price to Book - 6.86 x - - - -
Nbr of stocks (in thousands) 6,045 9,629 12,014 17,937 17,937 -
Reference price 2 13.55 17.04 5.050 2.150 2.150 2.150
Announcement Date 3/8/21 3/8/22 3/7/23 3/5/24 - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net sales 1 1.427 0.049 - 2.822 5 9.7
EBITDA 1 - -14.26 - -17.56 -17.1 -15.5
EBIT 1 - -17.08 - -20.24 -19.6 -18
Operating Margin - -34,851.02% - -717.12% -392% -185.57%
Earnings before Tax (EBT) 1 - - - -21.09 -19.6 -18
Net income 1 - - -22.75 -21.09 -19.6 -18
Net margin - - - -747.38% -392% -185.57%
EPS 2 -2.370 - -2.280 -1.560 - -
Free Cash Flow 1 - - - -18 - -
FCF margin - - - -529.41% - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/8/21 3/8/22 3/7/23 3/5/24 - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q1 2023 Q2 2023 Q3 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4
Net sales 1 - 1.181 1.08 0.8 1 1.8 1.4 1.8
EBITDA 1 - -5.245 -3.319 -4.6 -4.4 - -4.2 -3.9
EBIT 1 - -5.978 -4.026 -5.2 -5.1 - -4.8 -4.5
Operating Margin - -506.18% -372.78% -650% -510% - -342.86% -250%
Earnings before Tax (EBT) -5.034 - - - - - - -
Net income -5.034 - - - - - - -
Net margin - - - - - - - -
EPS - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 5/25/23 8/15/23 10/17/23 - - - - -
1SEK in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - 4 - -
Net Cash position 1 - - - - 6.2 -
Leverage (Debt/EBITDA) - - - -0.2564 x - -
Free Cash Flow 1 - - - -18 - -
ROE (net income / shareholders' equity) - -107% - -169% - -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share - 2.480 - - - -
Cash Flow per Share - - - - - -
Capex - 3.33 - - - -
Capex / Sales - 6,795.92% - - - -
Announcement Date 3/8/21 3/8/22 3/7/23 3/5/24 - -
1SEK in Million
Estimates
  1. Stock Market
  2. Equities
  3. CMOTEC B Stock
  4. Financials Scandinavian ChemoTech AB